Effectiveness of adding dopamine agonist therapy to long-acting somatostatin analogues in the management of acromegaly

Dinesh Selvarajah, Jonathan Webster, Richard Ross and John Newell-Price
Division of Clinical Sciences North, University of Sheffield, Northern General Hospital, Sheffield S5 7AU, UK

(Correspondence should be addressed to J Newell-Price; Email: j.newellprice@sheffield.ac.uk)

Abstract

Background: The excess mortality and morbidity associated with acromegaly are secondary to prolonged elevation of GH and IGF-I. Vigorous control of these biochemical parameters results in improved morbidity and mortality. Somatostatin analogues (SAs) allow adequate control of GH and IGF-I in approximately 65% of subjects, leaving a significant cohort uncontrolled. Dopamine agonists (DAs), a cheap alternative to SAs, allow control of GH and IGF-I in less than 20% of patients with acromegaly.

Aims: To assess the effectiveness of adding DA therapy to SA in the biochemical control of acromegaly.

Subjects: One hundred and twenty cases from the Sheffield Acromegaly Register were reviewed; 24 (20%) did not require medical treatment following pituitary surgery alone; 16 (13%) had safe GH levels following surgery and radiotherapy; and 58 (48%) required medical treatment despite having had surgery, radiotherapy or both. The remaining 22 (18%) received only medical treatment.

Methods: In nine subjects a DA (three bromocriptine, six cabergoline) was added to an SA to control active disease. GH day curves and IGF-I levels were compared before and after the addition of a DA to existing SA treatment. All were on stable maximum-dose treatment with an SA, with inadequate biochemical control prior to addition of DA therapy. Mean duration of treatment on a DA before biochemical assessments were made was 10.3 months. Six subjects had previously been treated with either transsphenoidal surgery, radiotherapy or both. In three subjects SA was the primary therapy.

Results: All subjects exhibited a fall in median GH and IGF-I levels. Introduction of a DA resulted in a 36.1% reduction in median GH levels (8.3 vs 5.3 mIU/l; P = 0.008) on a GH day curve and a 35.2% reduction in IGF-I levels (387.2 vs 251.0 mg/l; P = 0.018). Only four subjects had elevated prolactin levels prior to the addition of a DA (3.368 mIU/l).

Conclusion: Addition of DAs to SAs is of benefit in the biochemical control of acromegaly and should be considered in those inadequately controlled. Furthermore, the beneficial effects of DAs occur even when pre-treatment prolactin levels are within the normal range.
faster with stereotactic radiosurgery, but long-term data are still awaited (14, 15).

Recent advances in medical treatment have raised the prospect of obtaining biochemical control in virtually every subject, with consequent relief of symptoms and restoration of life expectancy to normal. In the past decade dopamine agonists (DAs) have been superseded by somatostatin analogues (SAs) as the mainstay of medical treatment for acromegaly. In particular, the long-acting formulations of octreotide and lanreotide allow dosing at intervals from 2 to 6 weeks, and have become the primary means of medical treatment. These later agents are, however, expensive and may still have a role as combination treatment with SAs in achieving safe GH/IGF-I levels in those partial/non-responders to SAs (18). This study investigated the effectiveness in clinical practice of the addition of a DA to an SA, in the routine treatment of inadequately controlled acromegaly.

Materials and methods

A retrospective review was performed on subjects in the Sheffield Acromegaly Register. This register contains the clinical details of all subjects referred to the Sheffield Teaching Hospitals with acromegaly. Date of diagnosis, details of surgery, radiotherapy and commencing/discontinuing medical treatment were noted. Mean GH levels measured as five samples over the day, IGF-I and prolactin levels performed to assess effects of interventions at various time points during an individual subject’s care were noted. Our intention was to specifically assess the effect of the addition of a DA to SA therapy in those individuals who had not fully responded to SA therapy alone. Thus, from this dataset, all subjects who had had a DA added to pre-existing SA treatment because of inadequate biochemical control when on the SA alone were identified, and are, therefore, a consecutive series of patients. To minimise selection bias any subject who had previously received DA therapy prior to SA treatment was not included.

The effect of this combination treatment was analysed. GH day curves and IGF-I levels were compared before and after the commencement of combined DA and SA treatment.

Assays

GH (Immulite Growth Hormone; DPC, Los Angeles, CA, USA), prolactin (Bayer Centaur, previously Abbot AxSym; Newbury, Berks, UK) and IGF-I (Nichols, San Juan de Capistrano, CA, USA) were assayed by immuno-chemiluminescence and IRMA after acid–ethanol extraction respectively. A reference range study performed with DPC’s Immulite GH kit on 62 samples from apparently healthy adults yielded the following results: an absolute range for GH of 0.06–5.0 ng/ml. The GH assay has a calibration range of up to 40 ng/ml. To convert ng/ml to mIU/l in terms of the World Health Organization’s International Reference Preparation Number 80/505, multiply by 2.6. Intra-assay and inter-assay coefficients of variation for the GH assay were 5.3–6.5 and 5.5–6.1% respectively. Normal ranges for the IGF-I assay (µg/l) are at 20–24 years, 116–447 (female), 133–498 (males); at 25–40 years, 96–302 (females and males); at 40–50 years, 80–276 (males and females); at 50–60 years, 65–251 (male and females); at 60–70 years, 52–227 (male and females); at 70–80 years, 40–204 (males and females); and at >80 years, 29–182 (males and females). Intra-assay and inter-assay coefficients of variation for the IGF-I assay were 3.3–4.6 and 9.3–15.8% respectively. Normal ranges for prolactin used for males and females over the age of 18 years were 45–375 and 59–619 mIU/l respectively.

Statistical analysis

All analysis was performed using the statistical package SPSS 11.1. Baseline characteristics and outcome variables (GH and IGF-I levels) were described as means and s.e.m. for normally distributed variables and as medians and 25th and 75th percentiles for variables with a skewed distribution. The Kolmogorov–Smirnov test was used to assess normality of distribution. The Wilcoxon signed-ranks test was used to test the null hypothesis that two related medians are the same. The relationship between prolactin levels at diagnosis and change in GH and IGF-I levels on combination therapy was analysed using linear regression. All statistical tests were two tailed and P values of less than 0.05 were considered significant.

Results

A total of 120 cases from the Sheffield Acromegaly Register were reviewed. Of these subjects 24 out of 120 (20%) did not require medical treatment following pituitary surgery alone; 16 out of 120 (13%) had safe GH levels following surgery and radiotherapy and 58 out of 120 (48%) required medical treatment despite having had surgery, radiotherapy or both. The remaining 22 out of 120 (18%) received only medical treatment (Fig. 1).

In nine subjects a DA (three bromocriptine and six cabergoline) was added to SA to control active disease. These subjects had not received DA therapy previously. The demographics of the subjects are shown in Table 1. Mean (s.e.m.) age of subjects was 53.1 (7.1) years. Individual GH and IGF-I levels before and after addition of DA are shown in Table 2. All were on a
stable maximum-tolerated dose of SA treatment for an average of 18.3 (±4.8) months, with inadequate biochemical control prior to addition of DA treatment. The mean dose of cabergoline and bromocriptine used was 1.1 mg per week and 4.2 mg three times per day, respectively. In no subject was the DA withdrawn as a result of intolerable side-effects. Three subjects (subjects A, B and G) were treated with medical therapy only and

Table 1 Subject demographics and baseline characteristics.

<table>
<thead>
<tr>
<th>Subject</th>
<th>A</th>
<th>B</th>
<th>C</th>
<th>D</th>
<th>E</th>
<th>F</th>
<th>G</th>
<th>H</th>
<th>I</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>63</td>
<td>82</td>
<td>42</td>
<td>49</td>
<td>71</td>
<td>30</td>
<td>79</td>
<td>37</td>
<td>25</td>
</tr>
<tr>
<td>RT (years before)</td>
<td>None</td>
<td>None</td>
<td>8.0</td>
<td>9.0</td>
<td>16.0</td>
<td>5.0</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Surgery</td>
<td>None</td>
<td>None</td>
<td>TPS</td>
<td>None</td>
<td>TPS</td>
<td>TPS</td>
<td>None</td>
<td>TPS</td>
<td>None</td>
</tr>
<tr>
<td>SA (µg)</td>
<td>LAR 30</td>
<td>LAR 30</td>
<td>LAR 30</td>
<td>LAR 30</td>
<td>LAR 30</td>
<td>Oct 500</td>
<td>LAR 30</td>
<td>Oct 400</td>
<td>LAR 30</td>
</tr>
<tr>
<td>CB mg (per week)</td>
<td>1.0</td>
<td>–</td>
<td>1.0</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>1.5</td>
<td>–</td>
<td>1.0</td>
</tr>
<tr>
<td>BR mg (tds)</td>
<td>–</td>
<td>10</td>
<td>–</td>
<td>2.5</td>
<td>5.0</td>
<td>2.5</td>
<td>–</td>
<td>1.0</td>
<td>–</td>
</tr>
<tr>
<td>Prolactin (mIU/l)</td>
<td>6310</td>
<td>53</td>
<td>154</td>
<td>2853</td>
<td>383</td>
<td>143</td>
<td>1570</td>
<td>626</td>
<td></td>
</tr>
</tbody>
</table>

TPS, transsphenoidal surgery; RT, three-field external beam fractionated radiotherapy at years from assessment made on combination therapy; N/A, not available; LAR 30, depot octreotide 30 µg monthly; Oct 400, octreotide 400 µg three times a day (tds); Oct 500, octreotide 500 µg tds; CB, cabergoline; BR, bromocriptine.

Table 2 GH (mIU/l) IGF-I (µg/l) levels and duration (months) pre- and post-addition of dopamine agonist to somatostatin analogue treatment.

<table>
<thead>
<tr>
<th>Subject</th>
<th>Duration</th>
<th>GH</th>
<th>IGF-I</th>
<th>GH</th>
<th>IGF-I</th>
<th>IGF-I normal range</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>20</td>
<td>6.3</td>
<td>322</td>
<td>2.7</td>
<td>206</td>
<td>52–227</td>
</tr>
<tr>
<td>B</td>
<td>51</td>
<td>11.3</td>
<td>297</td>
<td>8.3</td>
<td>197</td>
<td>26–182</td>
</tr>
<tr>
<td>C</td>
<td>17</td>
<td>6.5</td>
<td>387.2</td>
<td>2.4</td>
<td>211</td>
<td>80–276</td>
</tr>
<tr>
<td>D</td>
<td>23</td>
<td>18.3</td>
<td>505.8</td>
<td>3.3</td>
<td>255</td>
<td>80–276</td>
</tr>
<tr>
<td>E</td>
<td>24</td>
<td>6.5</td>
<td>698</td>
<td>6.2</td>
<td>290</td>
<td>40–204</td>
</tr>
<tr>
<td>F</td>
<td>1</td>
<td>12.9</td>
<td>N/A</td>
<td>4.8</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>G</td>
<td>13</td>
<td>8.3</td>
<td>302</td>
<td>6.0</td>
<td>251</td>
<td>40–204</td>
</tr>
<tr>
<td>H</td>
<td>6</td>
<td>93</td>
<td>N/A</td>
<td>46</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>I</td>
<td>10</td>
<td>6.4</td>
<td>680</td>
<td>5.3</td>
<td>608</td>
<td>127–360</td>
</tr>
</tbody>
</table>

18.3 (±4.8) 8.3 (6.4–15.6) 387.2 (302–680) 14.3 (2.3) 5.3 (3.0–7.3) 251 (206–290)

*Mean and S.E.M. *Median and 25th–75th percentile range.
six had either transsphenoidal surgery, or radiotherapy or both. In four subjects (subjects C, D, E and F) the mean duration between radiotherapy and commencement of combination treatment was 9.5 (2.3) years. In two subjects (subjects F and H) there were insufficient data on IGF-I levels before and after addition of DA, hence they were excluded from subsequent IGF-I sub-analysis.

Before combination treatment the median (range: 25th–75th percentile) GH and IGF-I levels were 8.3 mIU/l (6.4–15.6) and 387.2 μg/l (302–680) respectively (Fig. 2). Mean duration of treatment on a DA before biochemical assessments were made was 14.3 (2.3) months. Median GH and IGF-I level on combination therapy were 5.3 mIU/l (3.0–7.25) and 251 μg/l (206–290) (Fig. 2).

All subjects exhibited a fall in GH and IGF-I levels post addition of DA (Fig. 3). Introduction of a DA resulted in a 36.1% reduction in median GH levels (8.3 vs 5.3 mIU/l; P = 0.008) on a GH day curve and a 35.2% reduction in median IGF-I levels (387.2 vs 251.0 μg/l; P = 0.018). Four subjects (subjects A, C, D and F; 44% of the whole series) reached safe GH levels (<5 mIU/l) and three subjects (subjects A, C and D; 33% of the whole series) had normal age-adjusted IGF-I levels.

Only four subjects (subjects A, D, H and I; 44%) in this cohort had elevated prolactin levels (>368 mIU/l) at diagnosis. No significant correlation was found between prolactin levels at diagnosis and the fall in GH and IGF-I levels on combination therapy (P = 0.86 and 0.75 respectively).
Discussion

No single treatment for acromegaly is completely successful in controlling the disease and all its clinical manifestations, and different treatment modalities have advantages and disadvantages (10, 19). In deciding upon appropriate means to achieve biochemical control and relief of clinical manifestations the risk and benefits of each treatment modality needs to be optimised for each subject. SA remains the mainstay of medical treatment with oral DA as a second-line agent currently advocated with coexisting hyperprolactinaemia. There are, however, limited data on the therapeutic efficacy of combined use of SA and DA therapy (20). In a recent prospective study Cozzi et al. demonstrated the efficacy of the addition of DA to SA therapy (21). Interestingly, they showed that the presence of hyperprolactinaemia was not necessary to predict a response. Our data are in keeping with this. In contrast, previous studies assessing this combination have suggested that a response was seen only in those with hyperprolactinaemia (22). From a pragmatic perspective these data suggest that a trial of combined therapy should be considered in appropriate patients whether or not the circulating prolactin is elevated. We also studied the effects of the addition of two different DAs (bromocriptine and cabergoline) and found that both showed significant therapeutic efficacy. In addition, mean cabergoline dose used was lower in our study compared with that by Cozzi et al. (21) (1.1 vs 2.6 mg per week).

We have retrospectively analysed 120 cases of acromegaly and in nine subjects a DA was added to a stable maximum-dose treatment with SA. We assessed the effectiveness of this combined therapy in clinical practice and found that the addition of a DA to SA is of benefit in the biochemical control of acromegaly, and should be considered in those inadequately controlled. Whilst we expect that such an approach may be widespread, it is little documented. Although our study is limited by small numbers and its retrospective nature, our data add to the growing documentation of the efficacy and effectiveness of this combined therapy. Furthermore, the combined treatment appears to be well tolerated. Moreover, it gives support to the utility of such an approach in routine clinical practice, demonstrating the effectiveness of this combined therapy outside the tight confines of clinical trials. SA therapy causes at least 30% shrinkage in pituitary tumour volume in 73% of subjects with acromegaly (23). It seems likely that the addition of DA therapy will enhance this effect, although this will need testing in long-term studies with sequential imaging. The effects seen here on the levels of GH and IGF-I could potentially relate to the previous therapy that the subjects had received. The mean duration of SA therapy was 18.3 months (range 1–51) prior to the addition of the DA, with the levels of GH and IGF-I still being inadequately controlled. This makes it unlikely that the effects observed are due to the SA alone. In subjects F and H, however, the duration of treatment with SA alone was 1 and 6 months, prior to the addition of DA. It is possible that the effects we have observed are simply due to the effects of SA therapy when on prolonged treatment (23, 24), rather than due to the extra effects of DA therapy. In these individuals, however, the daily dose of SA was 1500 and 1200 μg octreotide s.c. given in three divided doses. Despite these high doses of non-depot SA their acromegaly remained inadequately controlled. Thus, it seems likely that the additional DA therapy was contributing to the beneficial effect observed. Similarly, four subjects had had pituitary radiotherapy 5–16 years before. Since radiotherapy is well documented to cause an initial exponential fall in GH (25) with levels then falling in a linear fashion, it is highly unlikely that the reduction in GH and IGF-I seen here over the short period of assessment (mean 13.3 months; range 7–29 months after the addition of DA) is caused by the previous radiotherapy.

It is possible that we could have selected those patients who were likely responders to DA therapy, but we have included analysis of all patients who had a DA added after stable SA therapy. None of these had received a DA previously. In this small cohort all appear to have responded, but it is likely that some patients will not show such a response and thus careful biochemical follow-up is needed in clinical practice to assess the effectiveness of this approach for a given patient.

Octreotide and lanreotide, the SA agents in common practice for the treatment of acromegaly bind predominantly to somatostatin receptor subtypes 2 and 5. Bromocriptine and cabergoline bind predominantly to dopamine D2 receptors. Elegant molecular analyses using fluorescent resonance energy transfer techniques have demonstrated hetero-dimerisation of somatostatin and dopamine receptors (26). It is likely that the effects seen here may involve receptor dimerisation, and synergistic action, although it may simply be the additive effect of combined therapy. Interestingly, the dose of DA used here is not very high (Table 1), which perhaps lends support to the effects being mediated by receptor dimerisation. Cozzi et al. (21) used higher doses, but the effects seen are similar in both that study and the data reported here. It is possible that the more prolonged period of administration at a lower dose achieved an effect similar to that seen for higher doses but of shorter duration. We can speculate whether addition of much higher doses could have been more effective, but this needs assessment in prospective studies.

Pegvisomant is an alternative agent for the treatment of acromegaly that blocks GH-receptor signalling, and hence lowers IGF-I and is a highly effective therapy for acromegaly, which has been shown to lower IGF-I in those not controlled on SA (27). Although now licensed for the therapy of acromegaly, pegvisomant is
extremely expensive and this limits its widespread use. The data presented here, and those of others, give strong support to the practice of adding DA therapy to those subjects inadequately treated with an SA, and then assessing if this improves control (18, 21).

In conclusion, we have confirmed the effectiveness of adding a DA treatment in subjects on stable SA therapy with inadequate control of disease. The effectiveness of this approach, however, needs assessment in each individual patient in whom it is used.

Acknowledgements

The authors would like to acknowledge the contribution of the endocrine nurses (Sister Betty Roberts, Sister Vicky Ibbotson, Staff Nurse Anita Doane and Sister Kay Dunkley) and Jayne Cunningham for assistance in sourcing and identifying subjects.

References


Received 19 December 2004
Accepted 13 January 2005